Get the Stockscreener App
63.00
0.63%
-0.40
After Hours:
62.76
-0.24
-0.38%
Monopar Therapeutics Inc stock is traded at $63.00, with a volume of 319.40K.
It is down -0.63% in the last 24 hours and down -16.49% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$63.40
Open:
$65.49
24h Volume:
319.40K
Relative Volume:
1.69
Market Cap:
$421.00M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-27.39
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-4.56%
1M Performance:
-16.49%
6M Performance:
+55.79%
1Y Performance:
+157.56%
1-Day Range:
$61.67
$66.64
1-Week Range:
$56.15
$66.64
52-Week Range:
$24.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
63.00 | 423.68M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
How dovish Fed policy supports Monopar Therapeutics Inc. (1IY0) stock2025 Market WrapUp & Weekly Watchlist for Hot Stocks - ulpravda.ru
Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Monopar Therapeutics initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley Initiates Coverage on Monopar Therapeutics (MNPR) - GuruFocus
Morgan Stanley initiates Monopar Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Why Monopar Therapeutics Inc. stock appeals to analystsPrice Action & Daily Growth Stock Tips - ulpravda.ru
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages - Defense World
Can Monopar Therapeutics Inc. stock maintain operating marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
How risky is Monopar Therapeutics Inc. stock nowWeekly Investment Recap & Free Community Consensus Stock Picks - ulpravda.ru
symbol__ Stock Quote Price and Forecast - CNN
Will Monopar Therapeutics Inc. stock return to pre crisis levelsJuly 2025 News Drivers & Fast Moving Stock Watchlists - ulpravda.ru
Can Monopar Therapeutics Inc. stock hit record highs again2025 Macro Impact & Weekly Return Optimization Alerts - ulpravda.ru
Published on: 2026-01-09 02:26:30 - ulpravda.ru
Published on: 2026-01-09 02:04:15 - ulpravda.ru
Will Monopar Therapeutics Inc. stock keep outperforming rivalsEntry Point & Low Risk Investment Opportunities - ulpravda.ru
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Trade Analysis & Capital Efficient Trade Techniques - ulpravda.ru
Published on: 2026-01-09 00:02:11 - ulpravda.ru
Published on: 2026-01-08 22:24:28 - ulpravda.ru
Trading the Move, Not the Narrative: (MNPR) Edition - Stock Traders Daily
EPS Watch: What dividend safety score for Monopar Therapeutics Inc. stock2025 Momentum Check & Verified Swing Trading Watchlists - moha.gov.vn
Monopar Therapeutics announces pricing of $135M offering - MSN
Aug Gainers: Why Monopar Therapeutics Inc stock appeals to analystsProfit Target & Fast Momentum Stock Entry Tips - moha.gov.vn
Hedge Fund Moves: Is Monopar Therapeutics Inc stock a buy for dividend growthSwing Trade & Technical Entry and Exit Alerts - moha.gov.vn
Top Executive Makes Bold Insider Move at Monopar Therapeutics - TipRanks
Insider Buying: Quan Vu Acquires Shares of Monopar Therapeutics Inc (MNPR) - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) CFO Purchases 1,500 Shares - MarketBeat
Monopar therapeutics CFO Vu Quan Anh buys $104925 in shares By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update - MarketBeat
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Zacks Investment Research
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
What dividend safety score for Monopar Therapeutics Inc. stockStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Major Insider Move Shakes Up Investor Watch on Monopar Therapeutics - TipRanks
Is Monopar Therapeutics Inc. stock a safe haven assetJuly 2025 Summary & Accurate Intraday Trading Signals - Улправда
Insider Sell: Arthur Klausner Sells Shares of Monopar Therapeuti - GuruFocus
Dir Klausner Files To Sell 5,121 Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics Director Sells Over 5,000 Shares - TradingView — Track All Markets
Monopar Therapeutics Insider Sold Shares Worth $343,889, According to a Recent SEC Filing - marketscreener.com
Dir Klausner Sells 5,121 ($343.9K) Of Monopar Therapeutics Inc [MNPR] - TradingView — Track All Markets
Monopar Therapeutics (FRA:1IY0) EV-to-OCF : -25.58 (As of Dec. 19, 2025) - GuruFocus
Why retail investors favor Monopar Therapeutics Inc. stock2025 Momentum Check & Community Shared Stock Ideas - DonanımHaber
Is Monopar Therapeutics Inc. (1IY0) stock a good hedge against inflation2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsGold Moves & High Accuracy Swing Trade Signals - Улправда
Treasury Yields: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivalsInsider Buying & Community Verified Trade Signals - Улправда
Monopar Therapeutics (MNPR) director details 43,499-share distribution in Form 4 - Stock Titan
Monopar Therapeutics (MNPR) director receives 7,710 common shares via distribution - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages - Defense World
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):